Inventor · disambiguated record
Bhaumik Pandya
Also filed as: PANDYA BHAUMIK · PANDYA BHAUMIK A
12 granted patents·24 pending applications·72 citations·filing 2013–2025
87Inventor score
Files withJANSSEN PHARMACEUTICA NV11CONCERT PHARMACEUTICALS INC10ALNYLAM PHARMACEUTICALS INC6YUMANITY THERAPEUTICS INC4VIGIL NEUROSCIENCE INC3
Top patents by PatentIndex Score
36 records- 0198US9249149B2Deuterated derivatives of ruxolitinibCONCERT PHARMACEUTICALS INC·Filed 2015·Granted Feb 2, 2016·62 cites·15 claims
- 0292US12275723B2Compounds and uses thereofJANSSEN PHARMACEUTICA NV·Filed 2023·Granted Apr 15, 2025·1 cites·16 claims
- 0387US2025025467A1Deuterated derivatives of ruxolitinibSUN PHARMACEUTICAL IND INC·Filed 2024·Application pending·0 cites
- 0486US11970486B2Compounds and uses thereofJANSSEN PHARMACEUTICA NV·Filed 2017·Granted Apr 30, 2024·3 cites·12 claims
- 0582US12180221B2Compounds and uses thereofJANSSEN PHARMACEUTICA NV·Filed 2020·Granted Dec 31, 2024·1 cites·20 claims
- 0682US2023355629A1Deuterated derivatives of ruxolitinibSUN PHARMACEUTICAL IND INC·Filed 2022·Application pending·0 cites
- 0780US2024300938A1Compounds and uses thereofJANSSEN PHARMACEUTICA NV·Filed 2024·Application pending·0 cites
- 0880US2025034125A1Compounds and uses thereofJANSSEN PHARMACEUTICA NV·Filed 2024·Application pending·0 cites
- 0980US2024400546A1Compounds and uses thereofJANSSEN PHARMACEUTICA NV·Filed 2024·Application pending·0 cites
- 1080US2025034124A1Compounds and uses thereofJANSSEN PHARMACEUTICA NV·Filed 2024·Application pending·0 cites
- 1179US11873298B2Compounds and uses thereofJANSSEN PHARMACEUTICA NV·Filed 2018·Granted Jan 16, 2024·1 cites·8 claims
- 1279US9145390B2Derivatives of pyrazole-substituted amino-heteroaryl compoundsCONCERT PHARMACEUTICALS INC·Filed 2013·Granted Sep 29, 2015·1 cites·12 claims
- 1377US9328113B2Substituted xanthine derivativesCONCERT PHARMACEUTICALS INC·Filed 2013·Granted May 3, 2016·3 cites·9 claims
- 1477US2025304569A1Compounds and uses thereofJANSSEN PHARMACEUTICA NV·Filed 2025·Application pending·0 cites
- 1574US2021330674A1Deuterated derivatives of ruxolitinibCONCERT PHARMACEUTICALS INC·Filed 2020·Application pending·0 cites
- 1668US2019308976A1Deuterated derivatives of ruxolitinibCONCERT PHARMACEUTICALS INC·Filed 2019·Application pending·0 cites
- 1767US2025042897A1Heterocyclic compounds as triggering receptor expressed on myeloid cells 2 agonists and methods of useVIGIL NEUROSCIENCE INC·Filed 2022·Application pending·0 cites
- 1866US12098146B2Compounds and uses thereofJANSSEN PHARMACEUTICA NV·Filed 2020·Granted Sep 24, 2024·0 cites·22 claims
- 1966US2015197525A1Deuterated derivatives of ruxolitinibCONCERT PHARMACEUTICALS INC·Filed 2014·Application pending·0 cites
- 2063US11241417B2Compositions and methods for the treatment and prevention of neurological disordersYUMANITY THERAPEUTICS INC·Filed 2019·Granted Feb 8, 2022·0 cites·8 claims
- 2163US2022110920A1Compositions and methods for the treatment and prevention of neurological disordersYUMANITY THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 2262US2017239254A1Deuterated derivatives of ruxolitinibCONCERT PHARMACEUTICALS INC·Filed 2017·Application pending·0 cites
- 2361US2025075217A1Peptide ligands for cns and ocular delivery of rnai compoundsALNYLAM PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 2460US2024318175A1Compositions and Methods for Silencing MYOC ExpressionALNYLAM PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 2560US2024409927A1Integrin targeting ligands for ocular delivery of rnai compoundsALNYLAM PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 2659US2025304580A1Heterocyclic compounds as triggering receptor expressed on myeloid cells 2 agonists and methods of useVIGIL NEUROSCIENCE INC·Filed 2025·Application pending·0 cites
- 2758US2024409943A1iRNA Compositions and Methods for Targeting ANGPTL7ALNYLAM PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 2856US9707218B2Derivatives of pyrazole-substituted amino-heteroaryl compoundsCONCERT PHARMACEUTICALS INC·Filed 2015·Granted Jul 18, 2017·0 cites·8 claims
- 2956US2024309003A1Heterocyclic compounds as triggering receptor expressed on myeloid cells 2 agonists and methods of useVIGIL NEUROSCIENCE INC·Filed 2022·Application pending·0 cites
- 3055US2025283071A1Modified double stranded oligonucleotidesALNYLAM PHARMACEUTICALS INC·Filed 2021·Application pending·0 cites
- 3155US2023136787A1Compositions and methods for silencing vegf-a expressionALNYLAM PHARMACEUTICALS INC·Filed 2021·Application pending·0 cites
- 3253US12268687B2Compounds and uses thereofJANSSEN PHARMACEUTICA NV·Filed 2020·Granted Apr 8, 2025·0 cites·29 claims
- 3352US2015299170A1Fluoro-derivatives of pyrazole-substituted amino-heteroaryl compoundsCONCERT PHARMACEUTICALS INC·Filed 2013·Application pending·0 cites
- 3447US10919885B2Compounds and uses thereofYUMANITY THERAPEUTICS INC·Filed 2019·Granted Feb 16, 2021·0 cites·16 claims
- 3547US2023078764A1Compounds and uses thereofYUMANITY THERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 3647US2015291594A1Deuterated PonatinibCONCERT PHARMACEUTICALS INC·Filed 2013·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Bhaumik Pandya files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →